BIOMAT Database Logo BIOMAT Database Logo

Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. 2010

David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Department of Emergency Medicine, Emergency Responder Human Performance Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

The clinical use of therapeutic hypothermia has been rapidly expanding due to evidence of neuroprotection. However, the effect of hypothermia on specific pathways of drug elimination in humans is relatively unknown. To gain insight into the potential effects of hypothermia on drug metabolism and disposition, we evaluated the pharmacokinetics of midazolam as a probe for CYP3A4/5 activity during mild hypothermia in human volunteers. A second objective of this work was to determine whether benzodiazepines and magnesium administered intravenously would facilitate the induction of hypothermia. Subjects were enrolled in a randomized crossover study, which included two mild hypothermia groups (4 degrees C saline infusions and 4 degrees C saline + magnesium) and two normothermia groups (37 degrees C saline infusions and 37 degrees C saline + magnesium). The lowest temperatures achieved in the 4 degrees C saline + magnesium and 4 degrees C saline infusions were 35.4 +/- 0.4 and 35.8 +/- 0.3 degrees C, respectively. A significant decrease in the formation clearance of the major metabolite 1'-hydroxymidazolam was observed during the 4 degrees C saline + magnesium compared with that in the 37 degrees C saline group (p < 0.05). Population pharmacokinetic modeling identified a significant relationship between temperature and clearance and intercompartmental clearance for midazolam. This model predicted that midazolam clearance decreases 11.1% for each degree Celsius reduction in core temperature from 36.5 degrees C. Midazolam with magnesium facilitated the induction of hypothermia, but shivering was minimally suppressed. These data provided proof of concept that even mild and short-duration changes in body temperature significantly affect midazolam metabolism. Future studies in patients who receive lower levels and a longer duration of hypothermia are warranted.

UI MeSH Term Description Entries
D007035 Hypothermia Lower than normal body temperature, especially in warm-blooded animals. Hypothermia, Accidental,Accidental Hypothermia,Accidental Hypothermias,Hypothermias,Hypothermias, Accidental
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008278 Magnesium Sulfate A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) Magnesium Sulfate, Heptahydrate,Heptahydrate Magnesium Sulfate,Sulfate, Magnesium
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D001831 Body Temperature The measure of the level of heat of a human or animal. Organ Temperature,Body Temperatures,Organ Temperatures,Temperature, Body,Temperature, Organ,Temperatures, Body,Temperatures, Organ
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Pharmacokinetics of propranolol in normal healthy volunteers.
June 1977, Journal of pharmacokinetics and biopharmaceutics,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers.
September 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
May 2009, Journal of clinical pharmacology,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers.
June 2001, Anesthesiology,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Rewarming of healthy volunteers after induced mild hypothermia: a healthy volunteer study.
March 2005, Emergency medicine journal : EMJ,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.
August 2006, Anesthesia and analgesia,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers.
May 2012, Clinical pharmacology and therapeutics,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers.
February 2002, British journal of clinical pharmacology,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers.
November 2009, Acta neurologica Scandinavica,
David Hostler, and Jiangquan Zhou, and Michael A Tortorici, and Robert R Bies, and Jon C Rittenberger, and Philip E Empey, and Patrick M Kochanek, and Clifton W Callaway, and Samuel M Poloyac
Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers.
May 2009, British journal of clinical pharmacology,
Copied contents to your clipboard!